Evidence map›Paper›PMID 25925868›Full record

ArticleJournal of translational medicine2015

Defining novel parameters for the optimal priming and expansion of minor histocompatibility antigen-specific T cells in culture.

Valérie Janelle, Cédric Carli, Julie Taillefer, Julie Orio, Jean-Sébastien Delisle

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 28 citations in OpenAlex.

  1. Spacing out dual checkpoint inhibition improves antigen-specific T cell manufacture.Molecular therapy. Methods & clinical development · 2023
    Article
  2. Combined PD-L1 and TIM3 blockade improves expansion of fit human CD8Molecular therapy. Methods & clinical development · 2022
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. The Bumpy Road to CAR Activation.Molecular therapy : the journal of the American Society of Gene Therapy · 2019
    Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Valérie JanelleCentre de recherche de l'Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada. vjanelle@pcitp.org.
Cédric CarliCentre de recherche de l'Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada. ccarli@pcitp.org.
Julie TailleferCentre de recherche de l'Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada. jtaillefer.pftr@gmail.com.
Julie OrioCentre de recherche de l'Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada. jorio@pcitp.org.
Jean-Sébastien DelisleCentre de recherche de l'Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada. js.delisle@umontreal.ca.
Hôpital Maisonneuve-Rosemont · CA

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

backgroundAdoptive transfer of minor histocompatibility antigen (MiHA)-specific T cells is a promising therapy for patients with hematological cancers. However, the efficacy of the transferred cells is hampered by the acquisition of terminal effector differentiation and exhaustion features during expansion in vitro thus preventing their function and persistence in vivo. Yet, the factors that induce T-cell differentiation and functional impairment in culture remain poorly defined and are likely to vary depending on the method used for expansion.

methodsUsing the clinically relevant HLA-A0201-restricted MiHA HA-1 as well as reagents and procedures that are readily transferable to a clinical environment, we designed a novel culture protocol and defined how exhaustion features appeared in function of time. The optimal time points for the expansion of "fit" MiHA-specific T cells were delineated using phenotypic and functional assessments including KLRG-1 and PD-1 surface markers as well as Ki67 staining and cytokine secretion assays.

resultsFollowing a priming phase, an enrichment step and a rapid expansion stage, our method generates MiHA-specific T-cell lines. Evidence of phenotypic and functional dysfunction appear in function of culture duration, but display different characteristics following the extension of the priming or rapid expansion phases. While repeated antigen exposure during the priming phase induced the decline of the antigen-specific population and the expression of PD-1 and KLRG-1 on antigen-specific CD8+ T cells, the prolongation of an antigen-free expansion phase induced proliferation arrest and the relative loss of antigen-specific cells without impairing polyfunctional cytokine secretion or inducing PD-1 and KLRG-1 expression. A similar pattern was also observed after stimulating a virus-specific memory repertoire, except for the more rapid acquisition of exhaustion features upon repeated antigen exposure.

conclusionOur results offer novel insights on the impact of culture duration on the acquisition of T-cell exhaustion features. Using a new clinical-compliant protocol, we define critical parameters to monitor in order to optimally differentiate and expand MiHA-specific T cells in culture prior to adoptive transfer.

Indexed as

BioreactorsCell LineCell ProliferationCoculture TechniquesEnzyme-Linked Immunosorbent AssayHumansImmunotherapy, AdoptiveMinor Lymphocyte Stimulatory AntigensT-LymphocytesMinor Lymphocyte Stimulatory Antigens

Identifiers

PMID25925868
PMCPMC4413989
OpenAlexW2086451783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.